Physician profile
Jeffrey Howard Nard
NPI 1184612426
$6,604.86
in general payments reported to CMS, 2019-2025
32 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $128 · 2021: $554 · 2022: $1,080 · 2023: $1,204 · 2024: $1,537 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,432 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,431.92 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.71 | 2021-2025 | |
| Corium, LLC | $503.67 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $480.09 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $391.58 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $381.20 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $379.60 | 2021-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $313.05 | 2019-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $295.53 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $294.28 | 2019-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $285.70 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $227.13 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $223.26 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $214.11 | 2021-2025 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $214.07 | 2020-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $197.54 | 2021-2025 | Aplenzin, Wellbutrin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $189.45 | 2022-2025 | Loreev Xr, Gralise |
| Neos Therapeutics, LP | $182.83 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Jazz Pharmaceuticals INC. | $170.30 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $167.48 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.17 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $148.16 | 2025 | Nuplazid |
| Tris Pharma INC | $132.61 | 2021-2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $99.74 | 2023-2024 | Austedo Xr |
| Validus Pharmaceuticals LLC | $78.31 | 2023-2024 | Equetro |
| Idorsia Pharmaceuticals US INC | $49.60 | 2023-2024 | Quviviq |
| Alfasigma USA, INC. | $39.27 | 2021 | |
| Harmony Biosciences LLC | $35.62 | 2025 | |
| Vertical Pharmaceuticals, LLC | $30.82 | 2025 | Relexxii |
| Allergan, INC. | $29.99 | 2020 | |
| Eisai INC. | $29.66 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $14.40 | 2025 | Jornay Pm |
| Neuronetics, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.